Biotron Limited Updates SedRx Regulatory Strategy After EMA Feedback, Advances Antiviral and Anaesthetic Programs

EMA Feedback Clarifies SedRx European Regulatory Pathway

During the quarter ending 30 June 2026, Biotron Limited received detailed feedback from the European Medicines Agency concerning the regulatory strategy for SedRx. The company had collaborated with an international regulatory advisory group to identify submission pathways for SedRx to the EMA. On 13 July 2026, after the quarter ended, Biotron announced the EMA's guidance on the suitability of various regulatory approaches for the anaesthetic candidate.

The EMA indicated that the Hybrid Marketing Authorisation Application pathway, which allows combining existing data from a previously approved drug with new clinical data, is not viable under current EU legislation. This is because the reference product, Althesin, is no longer commercially available, making necessary comparative bridging studies impossible. This clarification reduces regulatory uncertainty for Biotron by clearly indicating which pathway is not feasible.

SedRx Development Background and Therapeutic Benefits Compared to Current Standards

SedRx is formulated with alfaxalone, the active ingredient formerly used in Althesin, a general anaesthetic that dominated the day care anaesthetic market in the 1970s and 1980s before withdrawal due to safety concerns linked to its solubilising agent. Biotron’s subsidiary Sedarex holds global patents for SedRx, securing intellectual property protection across major regulatory regions.

Completed clinical trials suggest SedRx may offer significant advantages over propofol, the current standard general anaesthetic. Evidence points to particular benefits in populations vulnerable to post-anaesthetic neurocognitive impairment, such as older adults. This therapeutic differentiation could provide a competitive edge in a market prioritising anaesthetic safety and tolerability for at-risk patients.

Shift to Pivotal Clinical Trial Strategy for Marketing Authorisation

Biotron plans to maintain engagement with the EMA to establish a regulatory pathway for SedRx that complies with EU legislation and EMA requirements. Instead of the previously considered Hybrid MAA approach, the company will collaborate with the regulator to design pivotal clinical trials forming the basis of a future marketing authorisation application in Europe.

This pivot to pivotal trials aligns with standard regulatory practices for novel or reformulated drugs lacking prior approvals to leverage. The EMA’s guidance provides a clear roadmap, enabling Biotron to confidently advance toward regulatory submission supported by robust new clinical data.

Parallel Development of Additional Neuroscientific Indication

Alongside defining the regulatory pathway for SedRx as a general anaesthetic, Biotron continues R&D efforts exploring SedRx’s potential for another neuroscientific indication, undisclosed by the company. Current activities focus on drug procurement, assay development, and initiating animal studies to support clinical development rationale.

This dual-track approach allows Biotron to pursue multiple commercial opportunities for SedRx while advancing the primary anaesthetic indication toward approval. Discovering new therapeutic uses for an existing compound can extend its commercial lifespan and expand the target patient population. Progress in animal studies indicates the company’s commitment to this parallel development.

BIT-HBV001 Antiviral Program Expands to Target Hepatitis Delta Virus

During the June 2026 quarter, Biotron advanced evaluation of BIT-HBV001, its lead antiviral candidate for Hepatitis B virus infection, against Hepatitis Delta Virus. Cell-based assays are underway at the Scripps Institute in San Diego to investigate the antiviral’s mechanism of action against HBV and HDV co-infection. Data analysis is ongoing and will guide future development steps.

Expanding BIT-HBV001’s activity to include Hepatitis Delta Virus addresses a critical unmet need. HDV infects only individuals already carrying HBV, with an estimated 12 to 60 million people affected globally. Co-infection results in the most severe viral hepatitis form, often progressing rapidly to cirrhosis, liver failure, or hepatocellular carcinoma. Current treatment options for HBV/HDV co-infection remain very limited.

BIT-HBV001’s Potential Role in Functional Cure Therapies for Hepatitis B

Demonstrating BIT-HBV001’s activity against Hepatitis Delta Virus opens new therapeutic avenues for HBV patients facing limited treatments. Preliminary assays show inhibition of Hepatitis Delta antigen production in HBV/HDV co-infected cells, supporting continued development as part of future functional-cure therapies. These therapies aim to suppress viral replication and achieve sustained off-treatment control, offering meaningful clinical benefit despite not achieving full eradication.

BIT-HBV001’s potential inclusion in combination therapies targeting HBV/HDV co-infection represents a strategic opportunity to serve a severely affected patient population. The ongoing mechanism of action studies at Scripps will enhance understanding of this antiviral class, informing optimal combination regimens and clinical trial design. This expanded indication enhances the antiviral program’s commercial potential by addressing a high-need market.

R&D Tax Incentive Rebate Supports Ongoing Drug Development

In June 2026, Biotron received an R&D Tax Incentive rebate of $525,869 for the 2024/25 financial year, reflecting eligible research activities in its antiviral programs. This government grant from the Australian Tax Office supports the company’s investment in qualifying developmental work, improving cash flow during preclinical and early clinical stages.

The rebate partially offsets operating expenses amid multiple concurrent development programs. For the June 2026 quarter, Biotron reported $410,000 in R&D expenditure and $141,000 in related staff costs. Government grants totaling $526,000 during the quarter helped reduce net cash outflows, a vital funding source for development-stage biotech firms with limited commercial revenue.

Capital Structure Update Following Sedarex Share Escrow Release

In June 2026, 225,151,689 shares issued to Sedarex shareholders in December 2025 were released from voluntary escrow. This significant unlocking of shares marks a key capital structure event for Biotron, following the acquisition of Sedarex, which holds global patents for SedRx.

The release may impact Biotron’s trading volume and share price dynamics as these shares become freely tradable. Such escrow releases are typical in biotech mergers, providing a lock-up period to protect existing shareholders from immediate dilution. The large volume underscores the importance of the Sedarex acquisition to Biotron’s business.

Board Leadership Change with Appointment of Chairman Paul Kasian

On 15 May 2026, Michael J. Hoy retired as Biotron’s long-serving Chairman. Dr Paul Kasian, previously a Non-Executive Director, was appointed Chairman, ensuring continuity in governance during a critical phase of drug development with major programs progressing toward regulatory and clinical milestones.

Dr Kasian’s appointment maintains board familiarity with Biotron’s strategy and operations. This leadership transition coincides with clarified regulatory direction for SedRx in Europe and expanding development of BIT-HBV001. Seamless board handover is essential to minimize disruption during clinical-stage development and regulatory engagement.

Quarterly Operating Expenses and Cash Flow During Development Phase

According to Biotron’s Quarterly Cash Flow Report for June 2026, operating expenses reflected ongoing investment in drug development. R&D spending was $410,000, with $141,000 in related staff costs. Administration and corporate expenses totaled $211,000. Payments to related parties, including director fees and salaries, amounted to $141,000.

Net cash used in operating activities was $222,000 for the quarter, consistent with pre-revenue development-stage operations. Year-to-date operating cash outflows reached $1,777,000, including $716,000 in R&D and $588,000 in staff costs. Although the company did not disclose total cash reserves or burn rate guidance, the $525,869 R&D rebate materially offset cash outflows, supporting ongoing program funding.